Navigation Links
Potential cancer drug may offer new hope for asthma patients
Date:12/9/2009

A drug being tested to treat cancer could also help patients suffering from asthma, research has suggested.

Scientists at the University of Edinburgh found that the drug R-Roscovitine helps to kill certain immune cells which can exacerbate symptoms associated with asthma.

The findings could lead to an alternative way to treat asthma in patients who are resistant to steroids, which are commonly used in asthma treatments.

Researchers studied the effect that the drug had on immune cells known as eosinophils

Eosinophils, found in the lungs and airways, help the body fight off parasitic infection. However, too many uncontrolled eosinophils can damage other cells that line the lung, contributing to inflammatory conditions such as asthma.

Researchers found that use of the drug caused the eosinophil cells to undergo a form of cell death known as apoptosis, a natural process where unwanted cells are removed from the body.

Professor Adriano Rossi, of the Centre for Inflammation Research at the University of Edinburgh who directed the study, said: "Steroids are commonly used to treat asthma but can have unwanted side-effects, while some asthma patients are also resistant to steroid treatment. It may well be that use of a drug, such as R-Roscovitine, or one that works in a similar same way, could offer an alternative to steroids, or be used in conjunction with steroid treatment for asthma patients."


'/>"/>

Contact: Tara Womersley
tara.womersley@ed.ac.uk
44-131-650-9836
University of Edinburgh
Source:Eurekalert

Page: 1

Related biology news :

1. Pittsburgh scientists identify human source of stem cells with potential to repair muscle
2. Neuronal conduction of excitation without action potentials based on ceramide production
3. To maximize biofuel potential, researchers look for sorghums sweet spot
4. Joslin researchers uncover potential role of leptin in diabetes
5. Chemistry turns killer gas into potential cure
6. Researchers examine worlds potential to produce biodiesel
7. New inhibitor has potential as cancer drug
8. Potential new therapeutic molecular target to fight cancer
9. WCS study finds potential to double tiger numbers in South Asia
10. Childrens Hospital studying drug with the potential to prevent/delay onset of type 1 diabetes
11. Great potential to improve collection, recycling of Europes electronic waste, says UN report
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/19/2016)... , UAE, April 20, 2016 ... be implemented as a compact web-based "all-in-one" system solution ... the biometric fingerprint reader or the door interface with ... of modern access control systems. The minimal dimensions of ... ID readers into the building installations offer considerable freedom ...
(Date:4/13/2016)...  IMPOWER physicians supporting Medicaid patients in ... standard in telehealth thanks to a new partnership with ... IMPOWER patients can routinely track key health measurements, such ... and, when they opt in, share them with IMPOWER ... local retail location at no cost. By leveraging this ...
(Date:3/23/2016)... Massachusetts , March 23, 2016 /PRNewswire/ ... im Interesse erhöhter Sicherheit Gesichts- und Stimmerkennung ... Xura, Inc. (NASDAQ: MESG ), ... bekannt, dass das Unternehmen mit SpeechPro zusammenarbeitet, ... aus der Finanzdienstleistungsbranche, wird die Möglichkeit angeboten, ...
Breaking Biology News(10 mins):
(Date:6/23/2016)... -- The Prostate Cancer Foundation (PCF) is pleased to announce 24 new ... prostate cancer. Members of the Class of 2016 were selected from a pool ... Read More About the Class of 2016 PCF Young Investigators ... ... ...
(Date:6/23/2016)... , June 23, 2016   EpiBiome , a ... $1 million in debt financing from Silicon Valley Bank ... automation and to advance its drug development efforts, as ... facility. "SVB has been an incredible strategic ... services a traditional bank would provide," said Dr. ...
(Date:6/23/2016)... (PRWEB) , ... June 23, 2016 , ... STACS DNA ... Technical Leader at the Arkansas State Crime Laboratory, has joined STACS DNA as a ... STACS DNA team,” said Jocelyn Tremblay, President and COO of STACS DNA. “In further ...
(Date:6/23/2016)... , June 23, 2016 Apellis ... Phase 1 clinical trials of its complement C3 ... single and multiple ascending dose studies designed to ... (PD) of subcutaneous injection in healthy adult volunteers. ... (SC) either as a single dose (ranging from ...
Breaking Biology Technology: